AR026068A1 - Peptidos modificados y peptidomimeticos para el uso en inmunoterapia. - Google Patents

Peptidos modificados y peptidomimeticos para el uso en inmunoterapia.

Info

Publication number
AR026068A1
AR026068A1 ARP000105458A ARP000105458A AR026068A1 AR 026068 A1 AR026068 A1 AR 026068A1 AR P000105458 A ARP000105458 A AR P000105458A AR P000105458 A ARP000105458 A AR P000105458A AR 026068 A1 AR026068 A1 AR 026068A1
Authority
AR
Argentina
Prior art keywords
amino acids
formula
substitution
ser
thr
Prior art date
Application number
ARP000105458A
Other languages
English (en)
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of AR026068A1 publication Critical patent/AR026068A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Rehabilitation Therapy (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un péptido modificado derivado de H-Arg-Ser-Phe-Thr-Leu-Ala-Ser-Ser-Glu-Thr-Gly-Val-Gly-Oh (formula 1) que tiene la formula general Q-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12-A13-Z (formula 2). En la formula general 2 A1 a A13 corresponden a los aminoácidos de la formula 1, Q corresponde a H y Z corresponde a OH.Las modificaciones se seleccionan de uno o más de los grupos a, b, o c, consistentes en: a)sustitucion de 1-6 de preferencia 1-4 amino ácidos en A1 a A13 poramino ácidos no naturales obeta amino ácidos, b)sustitucion de uno o más enlaces amida por enlaces amida reducidos o isoesteres de etileno, c)sustitucionesen Q y/o Z y, opcionalmente, d)sustitucion por amino ácidos naturales, hasta un total de 6 modificaciones. Los péptidos pueden usarse para la induccion detolerancia en pacientes que sufren de enfermedades autoinmunes.
ARP000105458A 1999-10-18 2000-10-18 Peptidos modificados y peptidomimeticos para el uso en inmunoterapia. AR026068A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99203427 1999-10-18

Publications (1)

Publication Number Publication Date
AR026068A1 true AR026068A1 (es) 2002-12-26

Family

ID=8240756

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000105458A AR026068A1 (es) 1999-10-18 2000-10-18 Peptidos modificados y peptidomimeticos para el uso en inmunoterapia.

Country Status (23)

Country Link
EP (1) EP1226167A1 (es)
JP (1) JP2003512388A (es)
KR (1) KR20020047245A (es)
CN (1) CN1379786A (es)
AR (1) AR026068A1 (es)
AU (1) AU780238B2 (es)
BR (1) BR0014803A (es)
CA (1) CA2386398A1 (es)
CO (1) CO5271650A1 (es)
CZ (1) CZ20021356A3 (es)
HK (1) HK1046693A1 (es)
HU (1) HUP0203504A3 (es)
IL (1) IL148778A0 (es)
MX (1) MXPA02003520A (es)
NO (1) NO20021763L (es)
NZ (1) NZ518256A (es)
PE (1) PE20010692A1 (es)
PL (1) PL354590A1 (es)
RU (1) RU2002113107A (es)
SK (1) SK6842002A3 (es)
TR (1) TR200201036T2 (es)
WO (1) WO2001029081A1 (es)
ZA (1) ZA200202577B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002951212A0 (en) * 2002-09-04 2002-09-19 Monash University A method of modulating cellular activity and molecules for use therein
WO2007117665A2 (en) * 2006-04-06 2007-10-18 Purdue Research Foundation Derivatization-enhanced analysis of amino acids and peptides
US20100278745A1 (en) * 2006-12-21 2010-11-04 Norbert Lange Compounds for fluorescence imaging
WO2009092381A1 (en) 2008-01-23 2009-07-30 Herlev Hospital, Region Hovedstaden Ykl-40 as a general marker for non-specific disease
NZ592241A (en) 2008-09-15 2012-11-30 Herlev Hospital Ykl-40 as a marker for gastrointestinal cancers
CA2966865C (en) * 2014-11-07 2023-03-21 Kineta Chronic Pain, Llc Modifications and uses of conotoxin peptides
EP3466963A1 (en) * 2017-10-05 2019-04-10 Suigeneris Farmacosmetics, S.L. Anticancer peptides and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL115744A (en) * 1994-10-27 2000-07-16 Akzo Nobel Nv Peptides comprising a subsequence of human cartilage glycoprotein - 39
IL120561A0 (en) * 1996-04-24 1997-07-13 Akzo Nobel Nv Peptides suitable for use in immunosuppressive therapy
PL330348A1 (en) * 1996-06-07 1999-05-10 Zeneca Ltd Peptidic derivatives
IL122233A (en) * 1996-12-06 2001-04-30 Akzo Nobel Nv Method of generating monoclonal antibodies to cell wall and pharmaceutical preparations and diagnostic agents containing them

Also Published As

Publication number Publication date
HUP0203504A3 (en) 2005-03-29
IL148778A0 (en) 2002-09-12
CZ20021356A3 (cs) 2002-07-17
MXPA02003520A (es) 2002-08-20
PE20010692A1 (es) 2001-07-06
PL354590A1 (en) 2004-01-26
CN1379786A (zh) 2002-11-13
BR0014803A (pt) 2002-06-11
HK1046693A1 (zh) 2003-01-24
TR200201036T2 (tr) 2002-08-21
KR20020047245A (ko) 2002-06-21
AU780238B2 (en) 2005-03-10
HUP0203504A2 (hu) 2003-04-28
CO5271650A1 (es) 2003-04-30
AU1139601A (en) 2001-04-30
CA2386398A1 (en) 2001-04-26
RU2002113107A (ru) 2004-01-10
EP1226167A1 (en) 2002-07-31
WO2001029081A1 (en) 2001-04-26
NO20021763D0 (no) 2002-04-15
SK6842002A3 (en) 2002-09-10
NO20021763L (no) 2002-04-15
ZA200202577B (en) 2003-09-23
JP2003512388A (ja) 2003-04-02
NZ518256A (en) 2004-01-30

Similar Documents

Publication Publication Date Title
CO5700784A2 (es) Polipeptidos de virus de papiloma humano y composiciones in- munogenas
ES2564463T3 (es) Péptidos antigénicos de Neisseriales
ES2178000T3 (es) Composiciones y metodos para tratar infecciones usando analogos de indolicidina.
ATE280826T1 (de) Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen
DE60045524D1 (de) Ein Huhn GnRH-II Analog zur Verwendung in der Reduktion des Tumorzellwachstums
EA200400241A1 (ru) Направленные к мишени мультимерные контрастные вещества, основанные на пептидах
DE60030450D1 (de) Von MUC-1 abgeleitete Peptide
TR199802534T2 (xx) Leptin (OB Protein) fragmanlar�
ES2174770T1 (es) Peptidos diseñados para el diagnostico y el tratamiento de artritis reumatoide.
SG162791A1 (en) Mucin hypersecretion inhibitors based on the structure of mans and methods of use
PL1691827T3 (pl) Zastosowanie peptydów pochodzących z łańcucha beta ludzkiego fibrynogenu do leczenia wstrząsu
AR026068A1 (es) Peptidos modificados y peptidomimeticos para el uso en inmunoterapia.
YU53803A (sh) Peptidi i/ili proteini kao i njihova primena za pripremanje terapeutskih i/ili preventivnih lekova
DK0491628T3 (da) Lipopeptider inducerende cytotoksiske T-lymfocytter og deres anvendelse som vacciner
NZ592340A (en) A method for making a virus vaccine compising Replikin peptides
DE602004028266D1 (de) Angiogene peptide und ihre verwendungen
ATE355302T1 (de) N-substituierte d-aminosäuren enthaltende peptide,zur prävention der beta-strang assoziation
ATE385805T1 (de) Neue peptide
TW200505943A (en) Polypeptide
DK1504036T3 (da) Toxinrelaterede fragmenter af antistoffer med antimikrobiel og antiviral aktivitet
ECSP003720A (es) Peptidos modificados y peptidomimeticos para el uso en inmunoterapia
NZ570708A (en) Peptides of regulatory or accessory proteins of HIV, compositions and the utilization thereof
SE9700301D0 (sv) New compound
AR004497A1 (es) Un análogo hexapéptido cíclico de somatostatina, procedimiento para prepararlos y las composiciones farmacéuticas que los contienen y el uso de dicho hexapéptido para la preparación de una composición farmacéutica.
ID27162A (id) Peptida antigen tumor yang dibatasi hla-a2 yang berasal dari sart-1

Legal Events

Date Code Title Description
FB Suspension of granting procedure